Use of big data machine learning to study autoimmune diseases is on the rise, but little focus has been devoted…
José Lopes, PhD
José holds a PhD in neuroscience from the University of Porto, Portugal. After postdocs at Weill Connell Medicine and Western University, where he studied the processes driving hypertension and Alzheimer’s disease, he moved on in 2016 to a career in science writing and communication. José is the author of several peer-reviewed papers and a book chapter and has presented his research in numerous international meetings.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by José Lopes, PhD
Raynaud’s phenomenon and liver injury are among the risk factors for the development of pulmonary arterial hypertension (PAH) –…
Low salivary secretion contributes more to the altered oral microbiome found in people with primary Sjogren’s syndrome (pSS) than…
Patients with primary Sjogren’s syndrome (pSS) have high levels of an inflammatory protein known as interleukin-17 (IL-17), Chinese researchers…
Sjogren’s Patients with Chronic Dry Eyes Have High Medical Costs, High Anxiety, in Chinese Study
Sjogren’s syndrome patients with chronic dry eyes have higher medical costs than people with dry eyes who don’t have Sjogren’s,…
Immunosuppressants Can Help Chinese with Sjogren’s Syndrome-linked PAH Live Longer, Study Finds
Chinese who develop pulmonary arterial hypertension (PAH) from primary Sjogren’s syndrome have worse survival rates if their PAH appears late…
The protocol of a Phase 4 trial testing Wize Pharma‘s LO2A eye drops for the treatment of dry eye…
Pilocarpine Effectively Treats Mouth and Eye Dryness in Sjogren’s Syndrome, Phase 4 Trial Shows
Pilocarpine is an effective treatment for mouth and eye dryness in patients with Sjogren’s syndrome, a Phase 4 trial from…